Vimian Group AB (publ)

OTCPK:VIMG.F Stock Report

Market Cap: US$2.1b

Vimian Group Valuation

Is VIMG.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VIMG.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VIMG.F ($3.62) is trading below our estimate of fair value ($4.44)

Significantly Below Fair Value: VIMG.F is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VIMG.F?

Key metric: As VIMG.F is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VIMG.F. This is calculated by dividing VIMG.F's market cap by their current revenue.
What is VIMG.F's PS Ratio?
PS Ratio5.8x
Sales€352.39m
Market Cap€2.04b

Price to Sales Ratio vs Peers

How does VIMG.F's PS Ratio compare to its peers?

The above table shows the PS ratio for VIMG.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.3x
UFPT UFP Technologies
5.2x14.9%US$2.4b
NEOG Neogen
3.4x4.6%US$3.3b
VIVO Meridian Bioscience
4.5xn/aUS$1.5b
STAA STAAR Surgical
4.1x13.5%US$1.4b
VIMG.F Vimian Group
5.8x14.1%US$23.5b

Price-To-Sales vs Peers: VIMG.F is expensive based on its Price-To-Sales Ratio (5.8x) compared to the peer average (4.3x).

Price to Sales Ratio vs Industry

How does VIMG.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$232.94m
ARAY Accuray
0.4x5.5%US$204.15m
NVRO Nevro
0.4x2.5%US$170.50m
KEQU Kewaunee Scientific
0.6xn/aUS$122.17m
VIMG.F 5.8xIndustry Avg. 3.3xNo. of Companies50PS03.26.49.612.816+
50 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VIMG.F is expensive based on its Price-To-Sales Ratio (5.8x) compared to the US Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is VIMG.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VIMG.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VIMG.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VIMG.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.62
US$4.37
+20.6%
15.6%US$5.03US$3.27n/a6
Nov ’25n/a
US$4.34
0%
22.4%US$5.18US$2.65n/a6
Oct ’25n/a
US$4.35
0%
22.9%US$5.44US$2.75n/a7
Sep ’25n/a
US$4.03
0%
20.0%US$5.01US$2.70n/a7
Aug ’25n/a
US$3.74
0%
17.3%US$4.67US$2.63n/a7
Jul ’25n/a
US$3.63
0%
17.6%US$4.57US$2.60n/a7
Jun ’25n/a
US$3.69
0%
18.8%US$4.76US$2.63n/a7
May ’25n/a
US$3.57
0%
22.5%US$4.68US$2.46n/a6
Apr ’25n/a
US$3.64
0%
22.5%US$4.74US$2.54n/a6
Mar ’25n/a
US$3.78
0%
20.8%US$4.84US$2.69n/a7
Feb ’25n/a
US$3.60
0%
18.8%US$4.68US$2.70n/a7
Jan ’25n/a
US$3.64
0%
18.8%US$4.72US$2.72n/a7
Dec ’24n/a
US$3.68
0%
20.3%US$4.73US$2.64n/a6
Nov ’24n/a
US$3.82
0%
16.8%US$4.47US$2.54n/a6
Oct ’24n/a
US$3.98
0%
9.9%US$4.48US$3.32n/a6
Sep ’24n/a
US$4.02
0%
9.9%US$4.53US$3.35n/a6
Aug ’24n/a
US$4.15
0%
9.1%US$4.84US$3.62n/a6
Jul ’24n/a
US$4.12
0%
9.0%US$4.77US$3.57n/a6
Jun ’24n/a
US$4.16
0%
9.5%US$4.73US$3.53n/a6
May ’24US$3.85
US$4.02
+4.5%
12.3%US$4.86US$3.26n/a6
Apr ’24n/a
US$3.96
0%
12.4%US$4.77US$3.20n/a6
Mar ’24n/a
US$4.39
0%
21.5%US$5.84US$3.29n/a6
Feb ’24n/a
US$4.67
0%
20.2%US$5.99US$3.49n/a6
Jan ’24n/a
US$4.51
0%
20.0%US$5.68US$3.31n/a6
Dec ’23n/a
US$4.51
0%
20.0%US$5.68US$3.31n/a6
Nov ’23n/a
US$5.56
0%
30.8%US$7.59US$2.65n/a5

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Patterson Companies

US$1.9b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$21.49

7D

5.3%

1Y

-31.6%

Centene

US$31.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.00

7D

3.8%

1Y

-17.8%

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$89.53

7D

12.7%

1Y

29.8%